Stay updated on CA-4948 + FOLFOX/PD-1 +/- Trastuzumab Clinical Trial
Sign up to get notified when there's something new on the CA-4948 + FOLFOX/PD-1 +/- Trastuzumab Clinical Trial page.

Latest updates to the CA-4948 + FOLFOX/PD-1 +/- Trastuzumab Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. This is a minor site update with no changes to the study information.SummaryDifference0.0%

- Check19 days agoChange DetectedNo additions or deletions detected; the page content appears unchanged.SummaryDifference0.0%

- Check34 days agoChange DetectedThe inclusion criteria were expanded and clarified to define bone marrow and organ function thresholds, bleeding risk, and concomitant therapies (NSAIDs, antiplatelets, and anticoagulants), as well as requirements related to GI stents and endoscopic assessment. A previous blanket criterion of 'Normal bone marrow and organ function' was replaced with explicit definitions.SummaryDifference0.7%

- Check48 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check69 days agoChange DetectedAdded 'Gastric cancer' as a related topic and a new resources link to the Genetic and Rare Diseases Information Center on the study page.SummaryDifference0.1%

- Check76 days agoChange DetectedAdded Revision: v3.4.2; removed the government funding lapse notice and the older Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to CA-4948 + FOLFOX/PD-1 +/- Trastuzumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CA-4948 + FOLFOX/PD-1 +/- Trastuzumab Clinical Trial page.